A sensitive and reduced-cost culture medium for recovery of Clostridioides difficile isolates with reduced fidaxomicin susceptibility from stool [PDF]
Journal of Clinical MicrobiologyEmergence of resistance to fidaxomicin is a threat to current treatment algorithms for Clostridioides difficile infection (CDI), but current surveillance methods are labor-intensive and expensive. We tested the hypothesis that C. difficile Brucella agar (
Claire E. Kaple +7 more
doaj +2 more sources
Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection [PDF]
Antibiotics, 2023 Fidaxomicin, a macrocyclic antibiotic, selectively kills Clostridioides difficile and reduces C. difficile infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective.
Laura Whitney +2 more
doaj +2 more sources
The Impact of Hospital-Based Fidaxomicin Use Criteria on Clostridioides difficile Recurrence: A Retrospective Matched Cohort Study [PDF]
Infectious Disease ReportsBackground/Objectives: Clostridioides difficile infection (CDI) is associated with substantial morbidity and high recurrence rates. Current guidelines recommend fidaxomicin over oral vancomycin due to reduced recurrence; however, its high acquisition ...
Song Kwon +2 more
doaj +2 more sources
International Journal of Infectious Diseases, 2021 Purpose: We aimed to evaluate the efficacy of different antibiotic regimens for the treatment of Clostridioides difficile infection (CDI) with regard to the CDI episode number and disease severity.
Jiří Benes +2 more
exaly +3 more sources
Clinical failure of an extended-pulsed fidaxomicin regimen associated with emergence of a Clostridioides difficile isolate with reduced fidaxomicin susceptibility in an elderly man [PDF]
Antimicrobial Agents and ChemotherapyThe clinical significance of Clostridioides difficile isolates with reduced fidaxomicin susceptibility is uncertain. We report treatment failure of extended-pulsed fidaxomicin treatment during every other day pulsing associated with emergence of a C ...
Claire E. Kaple +8 more
doaj +2 more sources
Clinical and Pharmacoeconomic evaluation of Fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infection [PDF]
BMC Infectious DiseasesBackground Recurrent or refractory Clostridioides difficile infection (CDI) often affects older and immunocompromised patients, posing clinical and economic challenges.
Isabella Alram +6 more
doaj +2 more sources
Is Fidaxomicin Worth the Cost? An Economic Analysis [PDF]
Clinical Infectious Diseases, 2013 In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined.We developed a decision analytic simulation model to determine the economic value of fidaxomicin ...
Craig Umscheid +2 more
exaly +3 more sources
Gut MicrobesVancomycin and metronidazole are commonly used treatments for Clostridioides difficile infection (CDI). However, these antibiotics have been associated with high levels of relapse in patients. Fidaxomicin is a new treatment for CDI that is described as a
R Paul Ross, A Lavelle
exaly +3 more sources
RCSB Protein Data BankThe Formulary Management Expert Committee (FMEC) recommends that fidaxomicin be reimbursed for the treatment of Clostridioides difficile infection (CDI) in adult patients who have an initial episode or first recurrence of CDI and are at high risk for recurrence or are allergic to vancomycin, provided certain conditions are met. Fidaxomicin should be
Steven Arnold, Helen Gao
+7 more sources
Microbiology Spectrum, 2023 Fidaxomicin is an 18-membered glycosidic macrolide polyketide that was clinically used in the treatment of Clostridium difficile infection in 2011. Although the biosynthetic mechanism and pathway-specific regulator of fidaxomicin were well elaborated ...
Huang Xie +7 more
doaj +1 more source